Use of methyl pyruvate to increase cellular energy production downstream of glycolysis for the PARP-1 ablation of HIV without necrotic cell death caused by continuous, chronic PARP-1 activation through the concomitant depletion of ATP and NAD.
US2006052448A1
Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production.
US2006039935A1
Composition of a transdermal delivery system, which modulates inflammation, via insitu systems, thereby promoting repair of injured, damaged or diseased joints, and soft tissue.
US2006025476A1
Use of methyl pyruvate for the purpose of reducing weight gain in mammals.
US2006025475A1
Use of methyl pyruvate for the purpose of increasing muscle energy production.
